空许百年终不归吧 关注:59贴子:8,091
  • 9回复贴,共1

《每日脑残》又要过上不说人话的日子了

取消只看楼主收藏回复



IP属地:天津1楼2016-01-07 14:54回复
    http://www.ncbi.nlm.nih.gov/pubmed/16933260
    Gene expression profile of idiopathic thrombocytopenic purpura (ITP).
    特发性血小板减少性紫癜(ITP)的基因表达谱。
    To search for novel mechanisms that contribute to the pathophysiology of idiopathic thrombocytopenic purpura (ITP), we determined the whole blood gene expression profile in five ITP patients and five control samples. Using DNA microarrays that contained 24,473 unique putative genes, we found 176 cDNAs that were strongly correlated with ITP. These included a cluster of interferon-regulated genes and TLR7, as well many less-well characterized genes which are candidates for further study. We believe this approach is likely to yield new insights into our understanding of the molecular pathophysiology of ITP.
    寻找新的机制,有助于对特发性血小板减少性紫癜(ITP)的病理生理过程,测定全血基因表达谱对五例ITP患者和五个对照样本。利用DNA微阵列,包含24473个独特的基因,我们发现176个,ITP密切相关。这些包括一个集群干扰素调节基因的表达,也有许多不太好的特点,为进一步研究的候选基因。我们相信,这种方法可能会产生新的见解,我们对ITP的分子病理生理学理解。


    IP属地:天津2楼2016-01-07 14:56
    回复
      http://www.bloodjournal.org/content/122/10/1789.long?sso-checked=true
      Differences in gene expression and cytokine levels between newly diagnosed and chronic pediatric ITP.
      在新诊断的慢性儿童ITP的基因表达和细胞因子水平的差异。
      摘要: Immune thrombocytopenia (ITP) is an autoimmune disease where platelets are destroyed prematurely. In the majority of children the disease resolves, but in some it becomes chronic. To investigate whether these 2 phases of the disease are molecularly similar or separate entities we performed DNA microarray analysis (GEO accession number: GSE46922) of T-cells from newly diagnosed children and children with chronic ITP. We found complete separation of the gene expression profiles between the 2 phases of the disease. Furthermore, the gene expression levels of several cytokines differed between the 2 phases of the disease. This was also reflected in plasma with increased levels of interleukin (IL)-16 and TNF-related weak inducer of apoptosis and lower levels of IL-4 in newly diagnosed compared with chronic ITP. Thus, our data indicate that chronic ITP in childhood is a separate disease entity, dissimilar in many aspects to the newly diagnosed phase.
      免疫性血小板减少性紫癜(ITP)是一种自身免疫性疾病,血小板是过早破坏。在大多数的儿童疾病的解决,但在一些它成为慢性。探讨这2个阶段的疾病的分子相似的或单独的实体,我们进行了DNA微阵列分析(GEO登录号:gse46922)T细胞从新诊断的儿童和儿童慢性ITP患者。我们发现,完全分离的基因表达谱的2个阶段之间的疾病。此外,几个细胞因子的基因表达水平的2个阶段的疾病之间的差异。这也反映在增加白细胞介素(IL)16和血浆肿瘤坏死因子相关的弱凋亡诱导剂和较低水平的IL-4在新诊断的慢性ITP患者的比较。因此,我们的数据表明,在儿童慢性ITP是一种独立的疾病实体,不同的多方面的新诊断的阶段。


      IP属地:天津4楼2016-01-07 15:25
      回复
        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4001250/pdf/nihms461665.pdf
        The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP).
        1 r307hβ微管蛋白基因单核苷酸多态性与免疫性血小板减少性紫癜(ITP)治疗失败相关。
        摘要: Predictive biomarkers are needed in immune thrombocytopenia (ITP). Single nucleotide polymorphisms (SNPs) in beta 1 tubulin are potential candidates, as beta 1 tubulin is integral for platelet production and function, and SNPs in beta 1 tubulin have been associated with distinct phenotypes in platelets. We investigated the most prevalent beta 1 tubulin SNP (R307H) as a biomarker in patients with ITP via a retrospective chart review. Allelic frequencies between a group of 191 ITP patients and a healthy control group showed no difference, suggesting no direct aetiological role for the SNP in ITP. However, over similar periods of follow-up, both heterozygote and homozygote minor allele ITP patients were treated with significantly more treatment modalities and had significantly higher risk of failure to immune- modulatory therapies [ relative risk (RR) = 1.5, 95% confidence interval (CI) = 1.1-2.1; P = 0.01]; with rituximab, in particular, ITP patients with the SNP experienced a 58% failure rate (RR = 1.6, 95%CI = 1.03-2.5; P = 0.04). Analysis of the absolute immature platelet fraction (A-IPF) as a marker of platelet production showed that SNP patients had significantly higher median A-IPFs compared to non-SNP patients when complete responses were achieved using immune modulatory therapies. The data suggest that the beta 1 tubulin R307H SNP has potential for use as a biomarker in ITP and may affect platelet turnover.
        预测生物标志物在免疫性血小板减少性紫癜(ITP)的需要。β1微管蛋白的单核苷酸多态性(单核苷酸多态性)是潜在的候选人,作为β1微管蛋白是不可或缺的血小板的生产和功能,并在β1微管蛋白的单核苷酸多态性与不同的表型在血小板。我们研究了最常见的β-微管蛋白基因1(r307h)作为生物标志物在ITP患者进行回顾性分析。等位基因频率的一组191例ITP患者和健康对照组之间无显著差异,提示ITP的SNP没有直接病因的作用。然而,在随访期间均相似,杂合子和纯合子等位基因的ITP患者显着更多的治疗方式,治疗和免疫调节治疗失败[相对风险(RR)明显高于= 1.5,95%可信区间(CI)= 1.1-2.1;P = 0.01 ];利妥昔单抗,特别是特发性血小板减少性紫癜例SNP经历了58%失败率(RR = 1.6,95% CI = 1.03-2.5;P = 0.04)。绝对的未成熟血小板分数分析(a-ipf)作为血小板生成的标记表明SNP的患者有显着较高的平均a-ipfs相比非SNP的患者时,使用免疫调节治疗的完全反应了。数据表明,1的β微管蛋白r307h SNP具有潜在的使用作为生物标志物,并可能影响ITP血小板周转。


        IP属地:天津5楼2016-01-07 15:30
        回复
          http://www.ncbi.nlm.nih.gov/pubmed/22817814
          人类白细胞抗原(HLA)基因型
          杂合HLA-A11和HLA-Cw1等位基因频率均在ITP组显著降低,而杂合子hla-dq5频率在病例组明显增加。与HLA-DRB1 * 11或DRB1 15比治疗更可能对激素反应差的患者。此外,我们观察到HLA-A11纯合子和持续性或慢性ITP 。HLA-DRB1 * 08的存在,然而,随着持续性或慢性ITP的发展呈负相关。
          http://www.ncbi.nlm.nih.gov/pubmed/23249566
          FcgammaRIIA和相同基因多态性的作用
          http://www.ncbi.nlm.nih.gov/pubmed/23078136
          五个单核苷酸多态性(SNPs)的SDF-1基因,包括rs1801157,rs2839693,rs2297630,rs1065297,和rs266085
          http://www.ncbi.nlm.nih.gov/pubmed/21597364
          蛋白酪氨酸磷酸酶(PTPN22)存在于淋巴细胞为T细胞受体MHC复合物的一个重要的信号转导的负调控因子
          检测PTPN22 1858c > T突变


          IP属地:天津6楼2016-01-07 16:27
          回复
            http://www.ncbi.nlm.nih.gov/pubmed/17977208
            HLA-DRB1等位基因
            HLA-DRB1 * 07等位基因似乎对ITP的保护标志,HLA-DRB1 * 14等位基因可作为良好的ITP患者治疗反应的预测指标和有利的结果脾切除后。此外,HLA-DRB1 * 13等位基因在抗治疗的重要作用。
            http://www.ncbi.nlm.nih.gov/pubmed/20561430
            B细胞激活因子基因启动子多态性TNF家族(BAFF)- 871 C / T
            ITP初诊患者baff-871 C/T多态性和基因型
            http://www.ncbi.nlm.nih.gov/pubmed/21615796
            单核苷酸多态性的rs763780频率之间(7488t / C)
            http://www.ncbi.nlm.nih.gov/pubmed/23937109
            IL-27 rs153109多态性与免疫性血小板减少症的风险。 (中国阴性)


            IP属地:天津7楼2016-01-07 16:42
            回复
              http://www.ncbi.nlm.nih.gov/pubmed/20388659
              Short-course high-dose dexamethasone therapy for chronic idiopathic thrombocytopenic purpura in children.
              短疗程大剂量地塞米松治疗儿童慢性特发性血小板减少性紫癜
              在12例患者中,8例(66.6%)患者有完全的反应
              http://www.ncbi.nlm.nih.gov/pubmed/20218911
              High dose dexamethasone therapy shows better responses in acute immune thrombocytopenia than in chronic immune thrombocytopenia.
              大剂量地塞米松治疗急性免疫性血小板减少症,比慢性免疫性血小板减少症疗效好。
              急性免疫性血小板减少性紫癜应答率85.7%(12 / 14),慢性ITP整体反应率53%(8 / 15)
              响应时间的中位数为14天(4-42天)。
              十二名患者中20(5/12和7/8急性ITP慢性ITP)复发


              IP属地:天津8楼2016-01-19 09:43
              回复
                http://www.bloodjournal.org/content/124/22/3295.long?sso-checked=true
                clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis.
                儿童慢性免疫性血小板减少症的临床及实验室预测:系统回顾和荟萃分析
                重点:丙种球蛋白


                IP属地:天津9楼2016-01-19 10:10
                回复
                  http://www.bloodjournal.org/content/117/17/4569.long
                  The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP.
                  氧化应激


                  IP属地:天津10楼2016-01-19 10:23
                  回复
                    http://www.ncbi.nlm.nih.gov/pubmed/12638848
                    Levels of malondialdehyde, glutathione and ascorbic acid in idiopathic thrombocytopaenic purpura.
                    丙二醛、谷胱甘肽和抗坏血酸在紫癜
                    氧化应激相关指标


                    IP属地:天津11楼2016-01-19 10:42
                    回复